Stabilis

Lorazepam



Noms commerciaux

Ativan	Etats Unis d'Amérique, Grande Bretagne
Tavor	Italie
Temesta	Autriche, Belgique, France, Pays bas, Suisse

Stabilité des solutions

		0,038 mg/ml	21°C		24			350
		0,167 mg/ml	2-8°C	?	1			4248
		0,167 mg/ml	20-25°C	?	1			4248
		1 & 2 mg/ml	22°C		28			765
	∅	2 mg/ml	4°C-10°C		210			1424
PVC		0,038 mg/ml	21°C		24			350
PVC		1 mg/ml	25°C	?	24			935
PE		0,038 mg/ml	21°C		24			350
POF		0,1 mg/ml	-20°C		7			175
POF		0,1 mg/ml	24°C		7			175
POF		0,1 mg/ml	37°C		3			175
POF		0,1 mg/ml	4°C		7			175
POF		0,91 mg/ml	-20°C		35			1935

POF		0,91 mg/ml	24°C	?	35				1935
POF		0,91 mg/ml	37°C	?	5				1935
POF		0,91 mg/ml	4°C	?	35				1935
POF		0,2 mg/ml	25°C		24				2146
POF	RL	0,1 mg/ml	-20°C		7				175
POF	RL	0,1 mg/ml	24°C		7				175
POF	RL	0,1 mg/ml	37°C		3				175
POF	RL	0,1 mg/ml	4°C		7				175
PP		1 mg/ml	22°C		28				765
PP		0,167 mg/ml	2-8°C	?	2				4248
PP		0,167 mg/ml	20-25°C	?	4				4248

Stabilité en mélange

		0,05 mg/ml	20°C-23°C		Granisetron hydrochloride : 0,5 mg/ml	4	57
		1 mg/ml	25°C	?	Fosphenytoin sodium : 5 mg/ml	8	1419
		0,25 mg/ml	20°C-25°C	?	Palonosetron hydrochloride : 25 µg/ml	4	1975
		0,1 mg/ml	22°C-23°C		Milrinone lactate : 0,2 mg/ml	4	813
		0,028 mg/ml	25°C		Ondansetron hydrochloride : 0,44 mg/ml Dexamethasone sodium phosphate : 0,28 mg/ml	24	25
PP		0.16 mg/ml	25°C		Dexamethasone sodium phosphate : 0.27 mg/ml Diphenhydramine hydrochloride : 4 mg/ml	48	2132

Facteur influençant la stabilité

					1415
	PVC				24 25 175
	PVC				177 532
					233
	[0,5 mg/ml]				780

Compatibilités

		Lorazepam : 0.04 mg/ml Aciclovir sodium : 5 mg/ml	◆	336
		Lorazepam : 2 mg/ml Aldesleukin : 0.0338 MUI/ml	◆	36
		Lorazepam : 0.1 mg/ml Allopurinol sodium : 3 mg/ml	▲	307
		Lorazepam : 0.1 mg/ml Amifostine : 10 mg/ml	◆	3
		Lorazepam : 0.33 mg/ml Amikacin sulfate : 5 mg/ml	▲	186
		Lorazepam : 1 mg/ml Amiodarone hydrochloride : 6 mg/ml	◆	1611
		Lorazepam : 0.33 mg/ml Amoxicillin sodium : 50 mg/ml	▲	186
		Lorazepam : 4 mg/ml Amoxicillin sodium / clavulanic acid : 100/10 mg/ml		3824
		Lorazepam : 0.33 mg/ml Amoxicillin sodium / clavulanic acid : 20/2 mg/ml	▲	186
		Lorazepam : 0.1 mg/ml Amphotericin B cholesteryl sulfate complex : 0.83 mg/ml	◆	921
		Lorazepam : 0.1 mg/ml Amsacrine : 1 mg/ml	◆	253
		Lorazepam : 0.5 mg/ml Atracurium besylate : 0.5 mg/ml	◆	402
		Lorazepam : 0.1 mg/ml Aztreonam : 40 mg/ml	◆	99
		Lorazepam : 0.8 & 1.33 mg/ml Benztropine mesylate : 0.67 & 0.8 mg/ml	∅	1724
		Lorazepam : 0.5 mg/ml Bivalirudin		3539
		Lorazepam : 2 mg/ml Bivalirudin		3539
		Lorazepam : 0.5 mg/ml Bivalirudin : 5 mg/ml	◆	1713
		Lorazepam : 0.33 mg/ml Bumetanide : 0.5 mg/ml	▲	186
		Lorazepam : 4 mg/ml Caffeine : 10 mg/ml	∅	3964
		Lorazepam : 0,5 mg/ml Caspofungin acetate : 0,7 mg/ml	▲	2247
		Lorazepam : 1 mg/ml Cefiderocol sulfate tosylate : 20 mg/mL	▲◆	4528
		Lorazepam : 4 mg/ml Cefmetazole sodium : 100 mg/ml	●	93
		Lorazepam : 0.33 mg/ml Cefotaxime sodium : 10 mg/ml	▲	186
		Lorazepam : 0,5 mg/ml Ceftaroline fosamil : 2,22 mg/ml	▲◆	3249

	✓	Lorazepam : 0,5 mg/ml Ceftaroline fosamil : 2,22 mg/ml	RL	3249
	✓	Lorazepam : 0.5 mg/ml Ceftobiprole medocaril sodium : 2 mg/ml	RL	2269
	✓	Lorazepam : 0.5 mg/ml Ceftobiprole medocaril sodium : 2 mg/ml	▲◆	2269
	✓	Lorazepam : 1 mg/ml Ceftolozane / tazobactam : 10/5 mg/ml	▲◆	3828
↓	✗	Lorazepam : 0.44 & 0.8 mg/ml Chlorpromazine hydrochloride : 20 & 22.22 mg/ml	∅	1724
	✓	Lorazepam : 2 mg/ml Cimetidine hydrochloride : 150 mg/ml		1438
	✓	Lorazepam : 0.33 mg/ml Ciprofloxacin lactate : 2 mg/ml	▲	186
	✓	Lorazepam : 0.5 mg/ml Cisatracurium besylate : 0.1 >> 5 mg/ml	◆	299
	✓	Lorazepam : 0.1 mg/ml Cladribine : 0.015 mg/ml	▲	1496
	✓	Lorazepam : 0.1 mg/ml Cladribine : 0.5 mg/ml	▲+	1496
	✓	Lorazepam : 0.33 mg/ml Clonidine hydrochloride : 0.015 mg/ml	▲	186
4	✗	Lorazepam : 4 mg/ml Cloxacillin sodium : 100 mg/ml	●	3012
	✓	Lorazepam : 0.33 mg/ml Co-trimoxazole : 0.8/4 mg/ml	▲	186
	✓	Lorazepam : 0.33 mg/ml Dexamethasone sodium phosphate : 4 mg/ml	▲	186
	✓	Lorazepam : 0.5 mg/ml Dexmedetomidine : 4 µg/ml	▲	1712
	✓	Lorazepam : 4 mg/ml Diltiazem hydrochloride : 5 mg/ml	▲	198
	✓	Lorazepam : 0.5 mg/ml Diltiazem hydrochloride : 1 mg/ml		314
	✓	Lorazepam : 2 mg/ml Diltiazem hydrochloride : 1 mg/ml	▲	198
	✓	Lorazepam Dimenhydrinate		2087
	✓	Lorazepam : 0.5 mg/ml Dobutamine hydrochloride : 4 mg/ml		314
	✓	Lorazepam : 0.5 mg/ml Docetaxel : 0.9 mg/ml	◆	1754
	✓	Lorazepam : 0.5 mg/ml Dopamine hydrochloride : 3.2 mg/ml		314
	✓	Lorazepam : 0,5 mg/ml Doripenem : 5 mg/ml	▲◆	2262
	✓	Lorazepam : 0.1 mg/ml Doxorubicin hydrochloride liposome peg : 0.4 mg/ml	◆	251
	✓	Lorazepam : 0.5 mg/ml Epinephrine hydrochloride : 20 µg/ml		314
	✓	Lorazepam : 0.33 mg/ml Erythromycin lactobionate : 5 mg/ml	▲	186

	✓	Lorazepam : 2 mg/ml Etomidate : 2 mg/ml	∅	319
	✓	Lorazepam : 0.5 mg/ml Etoposide phosphate : 5 mg/ml	◆	1410
	✓	Lorazepam : 0.1 mg/ml Famotidine : 2 mg/ml	▲	215
	✓	Lorazepam : 0.5 mg/ml Fenoldopam mesylate : 80 µg/ml	▲	1803
	✓	Lorazepam : 0.1 mg/ml Fentanyl citrate : 25 µg/ml	◆	1974
	✓	Lorazepam : 0.5 mg/ml Fentanyl citrate : 50 µg/ml		314
	✓	Lorazepam : 0.33 mg/ml Fentanyl citrate : 50 µg/ml	▲	186
	✓	Lorazepam : 0.1 mg/ml Filgrastim : 30 µg/ml	◆	244
4	✗	Lorazepam : 0.33 mg/ml Flucloxacillin sodium : 50 mg/ml	▲	186
	✓	Lorazepam : 0.33 mg/ml Fluconazole : 2 mg/ml	▲	186
	✓	Lorazepam : 0.1 mg/ml		301
	✗	Lorazepam : 4 mg/ml	RL	4603
	✓	Lorazepam : 0.1 mg/ml Fludarabine phosphate : 1 mg/ml	◆	492
	✓	Lorazepam : 0,08 mg/ml Foscarnet sodium : 24 mg/ml	▲◆	1135
1	✗	Lorazepam : 0.1 mg/ml		1415
	✗	Lorazepam : 4 mg/ml Foscarnet sodium : 24 mg/ml	∅	73
	✓	Lorazepam : 1 mg/ml Fosfomycin : 30 mg/ml	▲◆	4055
	✓	Lorazepam : 1 mg/ml Fosphenytoin sodium : 5 mg/ml	▲	1419
	✓	Lorazepam : 0.5 mg/ml Furosemide : 10 mg/ml		314
	✓	Lorazepam : 0.33 mg/ml Furosemide : 10 mg/ml	▲	186
	✗	Lorazepam : 1 mg/ml Gallium nitrate : 1 mg/ml	▲	91
	✓	Lorazepam : 0.5 mg/ml Gemcitabine hydrochloride : 10 mg/ml	▲	1423
	✓	Lorazepam : 0.33 mg/ml Gentamicin sulfate : 3 mg/ml	▲	186
	✓	Lorazepam Glycopyrronium bromide		3599
	✓	Lorazepam : 0.1 mg/ml Granisetron hydrochloride : 1 mg/ml	▲	57
	✓	Lorazepam : 0.1 mg/ml Granisetron hydrochloride : 0.05 mg/ml	◆	182
	✓	Lorazepam : 0.33 mg/ml Haloperidol lactate : 0.5 & 5 mg/ml	▲	186

		Lorazepam : 0.33 mg/ml Heparin sodium : 417 UI/ml		186
		Lorazepam : 0.5 mg/ml Heparin sodium : 100 UI/ml		314
		Lorazepam : 0.5 mg/ml Hetastarch : 60 mg/ml		1721
		Lorazepam : 0.33 mg/ml Human albumin : 200 mg/ml		186
		Lorazepam Hyaluronidase		3617
		Lorazepam : 0.33 mg/ml Hydrocortisone sodium succinate : 50 mg/ml		186
		Lorazepam : 0.5 mg/ml Hydromorphone hydrochloride : 1 mg/ml		314
		Lorazepam : 4 mg/ml Hydromorphone hydrochloride : 2 >> 40 mg/ml		1497
		Lorazepam : 0.1 mg/ml Hydromorphone hydrochloride : 0.5 mg/ml		1974
		Lorazepam : 2 mg/ml Idarubicin hydrochloride : 1 mg/ml		491
		Lorazepam : 0.33 mg/ml Imipenem - cilastatin sodium : 5 mg/ml		186
		Lorazepam : 1 mg/ml Isavuconazonium sulfate : 1.5 mg/ml		3829
		Lorazepam : 4 mg/ml Ketamine hydrochloride : 50 mg/ml		4389
		Lorazepam : 4 mg/ml Ketamine hydrochloride : 50 mg/ml		2109
		Lorazepam : 0.5 mg/ml Labetalol hydrochloride : 2 mg/ml		314
		Lorazepam : 0.5 mg/ml Lansoprazole : 0.55 mg/ml		1625
		Lorazepam : 2 mg/ml Levofloxacine : 5 mg/ml		1072
		Lorazepam : 0.1 mg/ml Linezolid : 2 mg/ml		1925
		Lorazepam : 1.33 >> 2.67 mg/ml Loxapine : 16.67 >> 33.3 mg/ml		1724
		Lorazepam : 0.1 mg/ml Melphalan : 0.1 mg/ml		169
		Lorazepam : 0.1 mg/ml Methadone hydrochloride : 1 mg/ml		1974
		Lorazepam : 0.33 mg/ml Metronidazole : 5 mg/ml		186
		Lorazepam : 0.5 mg/ml Micafungin : 1.5 mg/ml		2108
		Lorazepam : 0.5 mg/ml Midazolam hydrochloride : 2 mg/ml		314
		Lorazepam : 0.5 mg/ml Milrinone lactate : 0.2 mg/ml		314
		Lorazepam : 0.4 mg/ml Milrinone lactate : 0.8 mg/ml		813

		Lorazepam : 0.33 mg/ml Morphine hydrochloride : 1 mg/ml	▲	186
		Lorazepam : 0.5 mg/ml Morphine sulfate : 2 mg/ml		314
		Lorazepam : 0.1 mg/ml Morphine sulfate : 1 mg/ml	◆	1974
15'		Lorazepam : 4 mg/ml Naloxone hydrochloride : 0.4 mg/ml	∅	3408
		Lorazepam : 0.5 mg/ml Nicardipine hydrochloride : 1 mg/ml		314
		Lorazepam : 0.5 mg/ml Nitroglycerin : 0.4 mg/ml		314
		Lorazepam : 0.5 mg/ml Norepinephrine bitartrate : 0.128 mg/ml		314
		Lorazepam : 0.33 mg/ml Omeprazole sodium : 4 mg/ml	▲	186
		Lorazepam : 0.1 mg/ml Ondansetron hydrochloride : 1 mg/ml	▲	334
		Lorazepam : 1 mg/ml Oritavancin : 0.8 >>2 mg/ml	◆	3152
		Lorazepam : 0,5 mg/ml Oxaliplatin : 0,5 mg/ml	◆	1662
		Lorazepam : 0.1 mg/ml Paclitaxel : 1.2 mg/ml	◆	85
		Lorazepam : 0,5 mg/ml Palonosetron hydrochloride : 50 µg/ml	◆	1975
		Lorazepam : 0.5 mg/ml Pancuronium bromide : 0.05 mg/ml	◆	402
		Lorazepam Pantoprazole sodium		2090
4		Lorazepam : 4 mg/ml Paracetamol : 10 mg/ml		4742
		Lorazepam : 0.5 mg/ml Pemetrexed disodium : 20 mg/ml	▲	1953
		Lorazepam : 0.33 mg/ml Piperacillin sodium : 150 mg/ml	▲	186
		Lorazepam : 0.1 mg/ml Piperacillin sodium / tazobactam : 40/5 mg/ml	◆	81
		Lorazepam : 1 mg/ml Plazomicin sulfate : 24 mg/ml	▲	4145
		Lorazepam Posaconazole		4380
		Lorazepam : 0.33 mg/ml Potassium chloride : 1000 mEq/l	▲	186
		Lorazepam : 2 mg/ml Propofol : 2 mg/ml	∅	319
		Lorazepam : 0.1 mg/ml Propofol : 10 mg/ml	∅	300
		Lorazepam : 4 mg/ml Ranitidine hydrochloride : 25 mg/ml	∅	58
		Lorazepam : 0.5 mg/ml Ranitidine hydrochloride : 1 mg/ml		314

		Lorazepam : 0.33 mg/ml Ranitidine hydrochloride : 0.5 mg/ml		186
		Lorazepam : 0.5 mg/ml Remifentanil hydrochloride : 25 & 250 µg/ml		59
		Lorazepam : 4 mg/ml Salbutamol sulfate : 1 mg/ml		3216
		Lorazepam : 0.1 mg/ml Sargramostim : 10 µg/ml		335
		Lorazepam : 0.1 mg/ml Sargramostim : 10 µg/ml		335
		Lorazepam : 1 mg/ml Tacrolimus : 1000 µg/ml		479
		Lorazepam : 1 mg/ml Tedizolid phosphate : 0.8 mg/ml		3827
		Lorazepam : 0.1 mg/ml Teniposide : 0.1 mg/ml		905
		Lorazepam : 4 mg/ml Thiopental sodium : 25 mg/ml		3767
		Lorazepam : 2 mg/ml Thiopental sodium : 25 mg/ml		319
		Lorazepam : 0.5 mg/ml Thiopental sodium : 25 mg/ml		314
		Lorazepam : 0.1 mg/ml Thiotepa : 1 mg/ml		249
		Lorazepam : 1 mg/ml Valproic acid : 2 & 20 mg/ml		4428
		Lorazepam : 0.33 mg/ml Vancomycin hydrochloride : 5 mg/ml		186
		Lorazepam : 0.5 mg/ml Vecuronium bromide : 0.1 mg/ml		402
		Lorazepam : 0.5 mg/ml Vecuronium bromide : 1 mg/ml		314
		Lorazepam : 0.33 mg/ml Vecuronium bromide : 4 mg/ml		186
		Lorazepam : 0.1 mg/ml Vinorelbine tartrate : 1 mg/ml		84
		Lorazepam : 0.08 mg/ml Zidovudine : 4 mg/ml		337

Voie d'administration

Bibliographie

	Type	Source
3	Revue	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
24	Revue	Stiles ML, Allen LV Jr, Prince SJ, Holland JS. Stability of dexamethasone sodium phosphate, diphenhydramine hydrochloride, lorazepam, and metoclopramide hydrochloride in portable infusion-pump reservoirs. Am J Hosp Pharm 1994 ; 51: 514-517.
25	Revue	McGuire TR, Narducci WA, Fox JL. Compatibility and stability of ondansetron hydrochloride, dexamethasone, and lorazepam in injectable solutions. Am J Hosp Pharm 1993 ; 50: 1410-1414.
36	Revue	Alex S, Gupta SL, Minor JR, Turcovski-Corrales S, Gallelli JF, Taub D, Piscitelli SC. Compatibility and activity of aldesleukin (recombinant interleukin-2) in presence of selected drugs during simulated Y-site administration: Evaluation of three methods. Am J Health-Syst Pharm 1995 ; 52: 2423-2426.
57	Revue	Mayron D, Gennaro AR. Stability and compatibility of granisetron hydrochloride in IV solutions and oral liquids and during simulated Y-site injection with selected drugs. Am J Health-Syst Pharm 1996 ; 53: 294-304.
58	Revue	Parker WA. Physical compatibility of ranitidine HCl with preoperative injectable medications. Can J Hosp Pharm 1985 ; 38: 160-161.
59	Revue	Trissel LA, Gilbert DL, Martinez JF, Kim MC. Compatibility of remifentanil hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2192-2196.
73	Revue	Lor E, Takagi J. Visual compatibility of foscarnet with other injectable drugs. Am J Hosp Pharm 1990 ; 47: 157-159.
81	Revue	Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 672-678.
84	Revue	Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499.
85	Revue	Trissel LA, Bready BB. Turbidimetric assessment of the compatibility of taxol with selected other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 1716-1719.
91	Revue	Lober CA, Dollard PA. Visual compatibility of gallium nitrate with selected drugs during Y-site injection. Am J Hosp Pharm 1993 ; 50: 1208-1210.
93	Revue	Hutchings SR, Rusho WJ, Tyler LS. Compatibility of cefmetazole sodium with commonly used drugs during Y-site delivery. Am J Health-Syst Pharm 1996 ; 53: 2185-2188.
99	Revue	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.

169	Revue	Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363.
175	Revue	Trissel LA, Pearson SD. Storage of lorazepam in three injectable solutions in polyvinyl chloride and polyolefin bags. Am J Hosp Pharm 1994 ; 51: 368-372.
177	Revue	Mancano MA, Boullata JI, Gelone SP, Zitterman RE, Borenstein MR. Avaibility of lorazepam after simulated administration from glass and polyvinyl chloride containers. Am J Health-Syst Pharm 1995 ; 52: 2213-2216.
182	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60.
186	Revue	Swart EL, Mooren RAG, Van Loenen AC. Compatibility of midazolam hydrochloride and lorazepam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2020-2022.
198	Revue	Gayed AA, Kheshary PR, Hinkle RL. Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 516-520.
215	Revue	Keyi X, Gagnon N, Bisson C, Desmarais M, LeBel M. Stability of famotidine in polyvinyl chloride minibags and polypropylene syringes and compatibility of famotidine with selected drugs. Ann Pharmacotherapy 1993 ; 27: 422-426.
233	Revue	Grillo JA, Barie PS. Precipitation of lorazepam during infusion by volumetric pump. Am J Health-Syst Pharm 1996 ; 53: 1850.
244	Revue	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
249	Revue	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
253	Revue	Trissel LA, Chandler SW, Folstad JT. Visual compatibility of amsacrine with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1990 ; 47: 2525-2528.
299	Revue	Trissel LA, Martinez JF, Gilbert DL. Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1735-1741.
300	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301	Revue	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
307	Revue	Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.

314	Revue	Chiu MF, Schwartz ML. Visual compatibility of injectable drugs used in the intensive care unit. Am J Health-Syst Pharm 1997 ; 54: 64-65.
319	Revue	Hadzija BW, Lubarsky DA. Compatibility of etomidate, thiopental sodium, and propofol injections with drugs commonly administered during induction of anesthesia. Am J Health-Syst Pharm 1995 ; 52: 997-999.
334	Revue	Trissel LA, Tramonte SM, Grilley BJ. Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 988-992.
335	Revue	Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 402-406.
336	Revue	Forman JK, Lachs JR, Souney PF. Visual compatibility of acyclovir sodium with commonly used intravenous drugs during simulated Y-site injection. Am J Hosp Pharm 1987 ; 44: 1408-1409.
337	Revue	Bashaw ED, Amantea MA, Minor JR, Galleli JF. Visual compatibility of zidovudine with other drugs during simulated Y-site administration. Am J Hosp Pharm 1988 ; 45: 2532-2533.
350	Revue	Martens HJ, De Goede PN, Van Loenen AC. Sorption of various drugs in polyvinyl chloride, glass, and polyethylene-lined infusion containers. Am J Hosp Pharm 1990 ; 47: 369-373.
402	Revue	Savitsky ME. Visual compatibility of neuromuscular blocking agents with various injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1990 ; 47: 820-821.
479	Revue	Min DI, Brown T, HWang GC. Visual compatibility of tacrolimus with commonly used drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 2964-2966.
491	Revue	Turowski RC, Durthaler JM. Visual compatibility of idarubicin hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2181-2184.
492	Revue	Trissel LA, Parks NPT, Santiago NM. Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2186-2189.
532	Revue	Hoey LL, Vance-Bryan K, Clarens DM, Wright DH, Konstantinides FN, Guay DRP. Lorazepam stability in parenteral solutions for continuous intravenous administration. Ann Pharmacotherapy 1996 ; 30: 343-346.
765	Revue	Share MJ, Harrison RD, Folstad J, Fleming RA. Stability of lorazepam 1 and 2 mg/ml in glass bottles and polypropylene syringes. Am J Health-Syst Pharm 1998 ; 55: 2013-2015.
780	Revue	Boullata J, Gelone SP, Mancano MA, Borenstein MR, Zitterman R. Precipitation of lorazepam infusion. Ann Pharmacotherapy 1996 ; 30: 1037-1038.
813	Revue	Akkermann SR, Zhang H, Mullins RE, Yaughn K. Stability of milrinone lactate in the presence of 29 critical care drugs and 4 IV solutions. Am J Health-Syst Pharm 1999 ; 56: 63-68.
905	Revue	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.

921	Revue	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
935	Revue	Das Gupta V, Pramar Y. Stability of lorazepam in 5% dextrose injection. Int J Pharm Compound 1998 ; 2: 322-324.
1072	Revue	Saltsmann CL, Tom CM, Mitchell A, Fan JH, Gailey RA. Compatibility of levofloxacin with 34 medications during simulated Y-site administration. Am J Health-Syst Pharm 1999 ; 56: 1458-1459.
1135	Revue	Baltz JK, Kennedy P, Minor JR, Gallelli J. Visual compatibility of foscarnet with other injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1990 ; 47: 2075-2077.
1410	Revue	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1415	Revue	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.
1419	Revue	Riggs RM, English BA, Webster AA, McGuire JM, Riordan JM. Fosphenytoin Y-site stability studies with lorazepam and midazolam hydrochloride. Int J Pharm Compound 1999 ; 3: 235-238.
1423	Revue	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1424	Revue	Gottwald MD, Akerd LC, Liu PK, Orsulak PJ, Corry M, Bacchetti P, Fields SM, Loxenstein DH, Alldredge BK. Prehospital stability of diazepam and lorazepam. Am J Emerg Med 1999 ; 17: 333-337.
1438	Revue	Souney PF, Solomon MA, Stancher D. Visual compatibility of cimetidine hydrochloride wih common preoperative injectable medications. Am J Hosp Pharm 1984 ; 41: 1840-1841.
1496	Revue	Trissel LA, Martinez JF, Gilbert DL. Screening cladribine for Y-site physical compatibility with selected drugs. Hosp Pharm 1996 ; 31: 1425-1428.
1497	Revue	Walker SE, Iazetta J, DeAngelis C, Lau DWC. Stability and compatibility of combinations of hydromorphone and dimenhydrinate lorazepam or prochlorperazine. Can J Hosp Pharm 1993 ; 46: 61-65.
1611	Revue	Chalmers JR, Bobek MB, Militello MA. Visual compatibility of amiodarone hydrochloride injection with various intravenous drugs. Am J Health-Syst Pharm 2001 ; 58: 504-506.
1625	Revue	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1662	Revue	Trissel LA, Saenz CA, Ingram DS, Ogundele AB. Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs. J Oncol Pharm Practice 2002 ; 8: 33-37.
1712	Revue	Trissel LA, Saenz CA. Compatibility screening of Precedex during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 230-233.
1713	Revue	Trissel LA, Saenz CA. Compatibility screening of bivalirudin during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 311-315.

1721	Revue	Trissel LA, Williams KY, Baker MB. Compatibility screening of Hextend during simulated Y-site administration with other drugs. Int J Pharm Compound 2001 ; 5: 69-72.
1724	Revue	Elbe D, Condé C. Visual compatibility of various injectable neuroleptic agents with benztropine and lorazepam in polypropylene syringes. Can J Hosp Pharm 2001 ; 54: 102-105.
1754	Revue	Trissel LA, Gilbert DL, Wolkin AC. Compatibility of docetaxel with selected drugs during simulated Y-site administration. Int J Pharm Compound 1999 ; 3: 241-244.
1803	Revue	Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85.
1925	Revue	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1935	Revue	Norenberg JP, Achusim LE, Steel TH, Anderson TL. Stability of lorazepam in 0.9% sodium chloride stored in polyolefin bags. Am J Health-Syst Pharm 2004 ; 61: 1039-1041.
1953	Revue	Trissel LA, Saenz CA, Ogundele AB, Ingram DS. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
1974	Revue	Chandler SW, Trissel LA, Weinstein SM Combined administration of opoids with selected drugs to manage pain and other cancer symptoms initial safety screening for compatibility. J Pain Symptom Manage 1996 ; 12, 3: 168-171.
1975	Revue	Trissel LA, Xu QA. Physical and chemical stability of palonosetron hydrochloride with lorazepam and midazolam hydrochloride during simulated Y-site administration. Int J Pharm Compound 2005 ; 9, 3: 235-237.
2087	Revue	Ferreira E, Forest JM, Hildgen P. Compatibility of dimenhydrinate injectable by Y administration. Pharmactuel 2004 ; 37: 17-20.
2090	Revue	Pere H, Chasse V, Forest JM, Hildgen P. Compatibility of injectable pantoprazole in Y-site administration. Pharmactuel 2004 ; 37: 193-196.
2108	Revue	Trusley C, Kupiec TC, Trissel LA. Compatibility of micafungin injection with other drugs during simulated Y-site co-administration. Int J Pharm Compound 2006 ; 10: 230-232.
2109	Revue	Pelletier E, Forest JM, Hildgen P. Compatibilité de la kétamine injectable lors de l'administration en dérivé avec d'autres médicaments usuels. Pharmactuel 2006 ; 39: 71-75.
2132	Revue	Anderson Collin R, Halford Zachery, MacKay Mark. Stability of Diphenhydramine Hydrochloride, Lorazepam, and Dexamethasone Sodium Phosphate in 0.9% Sodium Chloride Stored in Polypropylene Syringes. Int J Pharm Compound 2015 ; 19, 4 : 344-347.
2146	Revue	Trissel LA, Xu QA, Baker M. Drug compatibility with new polyolefin infusion solution containers. Am J Health-Syst Pharm 2006 ; 63: 2379-2382.
2247	Revue	Chan P, Heatherly K, Kupiec T.C, Trissel L.A. Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2008 ; 12, 3: 276-278.

2262	Revue	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administratioN Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
2269	Revue	Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H. Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.
3012	Revue	Sullivan T, Forrest J.M, Leclair G. Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration Hosp Pharm 2015 ; 50, 3: 214-220.
3152	Revue	Kumar A, Mann HJ. Visual compatibility of oritavancin diphosphate with selected coadministered drugs during simulated Y-site administration. Am J Health-Syst Pharm 2010 ; 67: 1640-1644.
3216	Revue	Legris ME, Valiquette ME, Lavoie A, Forest JM, Leclair G. Compatibilité physique par évaluation visuelle du salbutamol injectable lors de son administration en Y. Pharmactuel 2011 ; 44, 1 : 14-18
3249	Revue	Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB. Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
3408	Revue	Tollec S, Touzin K, Pelletier E, Forest J.M. Evaluation visuelle de la compatibilité physique de la naloxone avec d'autres médicaments intraveineux usuels. Pharmactuel 2013 ; 46, 1 : 16-21.
3539	Laboratoire	Bivalirudin (Angiox®) - Summary of Product Characteristics. The Medecines Company 2013
3599	Laboratoire	Glycopyrrolate Injection U.S.P. - Summary of Product Characteristics Amco Amdipharm Mercry 2013
3617	Laboratoire	Hyaluronidase (Hyalase®) - Summary of Product Characteristics Wockhardt 2011
3767	Revue	Legris M.E, Lavoie A, Forrest J.M, Hildgen P. Compatibilité par évaluation visuelle du thiopental injectable lors de son administration en Y avec des médicaments usuels. Pharmactuel 2014 ; 47, 3 : 167-172.
3824	Revue	Boudi S, Roy H, Forest JM, Leclair G. Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y. Pharmactuel 2023 2023;56,3:91-98
3827	Poster	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3828	Poster	Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	Poster	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
3964	Revue	Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G. Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments. Pharmactuel 2017 ; 50,1 : 27-33.
4055	Revue	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44

4145	Revue	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4248	Revue	Colsoul M.L, Breuer A, Goderniaux N, Hecq J.D, Soumoy L, Bihin B, Jamart J, Galanti L. Long-Term Stability of Lorazepam in Sodium Chloride 0.9% Stored at Different Temperatures in Different Containers. Hosp Pharm 2019 ; 55, 3: 199-193.
4380	Laboratoire	Posaconazole (Noxafil®) - Summary of Product Characteristics Merck Sharp & Dohme Limited 2019
4389	Revue	Côté K, Correal F, Metras M.E, Friciu M, Forest J.M, Leclair G. Compatibilité physique des médicaments administrés en Y aux soins intensifs, en particulier la dexmédétomidine, le lévosimendan et la kétamine. Pharmactuel 2019 ;52,4:206-213
4428	Revue	Rashed S.M, Sweatman T.W, Thoma L, Hovinga C.A, Phelps S.J. Chemical Compatibility of Depacon® with Medications Frequently Administered by Intravenous Y-Site Delivery in Patients with Epilepsy or Head Trauma. J Pediatr Pharmacol Ther 2004 ; 9, 2: 126-132.
4528	Revue	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4603	Revue	Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G. Compatibility of Lactated Ringer's Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration. Hosp Pharm 2021 ; 56, 4: 228-234.
4742	Revue	Macoviciuc M, Nguyen C, Forest J-M, Leclair G. Compatibilité physique de l'acétaminophène injectable avec 102 autres médicaments lors d'une administration en Y. Pharmactuel 2022 ; 55, 4: 247-255.

Stabilis

Lorazepam



Stabilité des préparations

		30 mg ® = Mylan	Eau ppi 13 mL OraPlus® 7,5 mL Orasweet ® 9,5 mL	21,5-22,5°C		91			4418
		30 mg ® = Watson laboratories	Orasweet ® 13,5 mL OraPlus® 12,5 mL Eau ppi 4 mL	21,5-22,5°C		42			4418
		30 mg ® = Mylan	Eau ppi 13 mL OraPlus® 7,5 mL Orasweet ® 9,5 mL	3-5°C		91			4418
		30 mg ® = Watson laboratories	Orasweet ® 13,5 mL OraPlus® 12,5 mL Eau ppi 4 mL	3-5°C		91			4418
		150 mg ® = ? (Fagron)	SyrSpend SF PH4® >>150 ml	2-8°C		90			3846
		150 mg ® = ? (Fagron)	SyrSpend SF PH4® >>150 ml	20-25°C		60			3846

Bibliographie

	Type	Source
3846	Revue	Polonini HC, Silva SL, Cunha CN, Brand?o MAF, Ferreira AO. Compatibility of cholecalciferol, haloperidol, imipramine hydrochloride, levodopa/carbidopa, lorazepam, minocycline hydrochloride, tacrolimus monohydrate, terbinafine, tramadol hydrochloride and valsartan in SyrSpend® SF PH4 oral suspensions. Pharmazie 2016 71: 185?191.
4418	Revue	Ellaria Lee W-M, Lugo R.A, Rusho W.J, MacKay M, Sweeley J. Chemical Stability of Extemporaneously Prepared Lorazepam Suspension at Two Temperatures. J Pediatr Pharmacol Ther 2004 ; 9, 4: 254-258.

Dictionnaire

	Anxiolytique		Injectable
	Noms commerciaux		Stabilité des solutions
	Contenant		Molécule
	Concentration		Température
	Conservation		Durée de stabilité
	Biosimilaire		Données conflictuelles
	Bibliographie		Verre
	Chlorure de sodium 0,9%		A l'abri de la lumière
	Heure		Non précisée
	Jour		Glucose 5%
	Lumière		Aucun
PVC	Polyvinyl chlorure	PE	Polyéthylène
POF	Polyolefine		NaCl 0,9% ou glucose 5%
RL	Ringer lactate		Seringue polypropylène
	Stabilité en mélange		Solvant
	Molécule	PP	Polypropylène
	Facteur influençant la stabilité		Nutrition parentérale (mélange ternaire)
	Provoque		Dégradation
	Adsorption		Absorption
	Pompe péristaltique		Précipitation
	Compatibilités		Compatible
	Précipitation immédiate		Incompatible
	Turbidité en 1 heure		Incompatibilité non précisée
	Eau pour préparation injectable		NaCl 0,9% + bactériosatique
	Turbidité en 4 heures		Nutrition parentérale (mélange binaire)
	Instabilité de l'émulsion en 1 heure		Dégagement gazeux
	Solvant spécifique		Changement de couleur
	Précipitation en 24 heures		Turbidité immédiate
	Précipitation en 15 minutes		Voie d'administration
	Perfusion intraveineuse		Intramusculaire

	Bibliographie		Solution buvable
	Stabilité des préparations		Origine
	Excipient		Comprimés
	Flacon plastique		Poudre
	Dictionnaire		